The Healing Power of Botanical Therapeutics®


China Health Resource Forwards Final Termsheet for Acquision of Herborium Group

Press Release: Herborium Group, Inc. — June 5 , 2012 8:45 AM EDT

SUINING, China, June 5, 2012 /PRNewswire-Asia/ -- China Health Resource, Inc. (CHRI), today announced it has issued a final termsheet to Herborium Group (OTC Pinksheets: HBRM) and is now awaiting response from the Herborium Board of Directors.

Steve Weiss, USA Director of Strategic Acquisitions and Financial Marketing stated, "I am most excited to have united and introduced both CHRI with HBRM and my hope is for a favorable outcome. As CHRI revenues continue to significantly break all time new highs in their TCM products in China it is my hope that these products will be introduced to all natural western markets with new domestic distribution channels."

"We are proceeding with our Go Global Initiative which includes setting-up headquarter operations in the USA and expansion into other key regions like Latin America and Africa where we find opportunities to grow our business," says Jiayin Wang, CEO of CHRI.

Press Contact:

Mr. Steven Weiss
Contact Tel. 732-513-6921(USA)
USA Rep for China Health Resource, Inc.

About CHRI

China Health Resource, Inc. engages in the development, manufacturing, processing, marketing and sale of raw and pharmaceutical TCM products including Dahurian Angelica Root (DAR) and Rhizoma Gastrodiae and is the only the provider of GAP quality DAR in the People's Republic of China under the registered Trademark Chuan Baizhi™. DAR, which is also known as "Bai Zhi" in Mandarin Chinese, is an herb that is employed as an ingredient in medicine, cosmetics and food, as well as used in TCM for the treatment of pain, swelling and pustule. The Company's DAR-related products include the Bailing Capsule, Yisheng Capsule, Kimchee-Mate and Fragrant Bag, all of which are sold through regional distributors. The Company was founded in 2001 and is based in Suining, Sichuan Province.

For more information visit

Certain statements in this document regarding financial matters, other than historical facts, and statements of our expectations, intentions, plans and beliefs, constitute "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to certain events, risks and uncertainties that may be outside our control. The words "believe", "expect", "anticipate", "optimistic", "intend", "will", and similar expressions identify forward-looking statements. The company intends that such proclamations about future expectations, including future revenues and earnings, future business expansion plans, and all other forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. These and other risks and uncertainties related to our business are described in greater detail in our filings with the Commission. The foregoing information should be read in conjunction with these filings. We disclaim any intention or obligation to update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made.

Information provided on about medical conditions, symptoms, and related products is not intended to be a substitute for professional medical advice. Visitors to this site should not use this information to diagnose or treat a health problem, symptom, concern or disease without consulting with their individual qualified healthcare provider. Statements contained on this website have not been evaluated by the FDA. Herborium products are not intended to diagnose, heal, cure or prevent disease.